Lenvima Receives Breakthrough Therapy Designation from FDA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted a Breakthrough Therapy Designation to Lenvima (lenvatinib) in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor-targeted therapy.

Lenvima is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Lenvima is not indicated for patients with metastatic renal cell carcinoma.

Lenvima received the designation based on results of a phase II open-label, multicenter study involving 153 patients who were previously treated with a VEGF-targeted therapy and randomized 1:1:1 to receive Lenvima and everolimus (18+5 mg once a day), Lenvima (24 mg once a day) or everolimus (10 mg once a day).

Nearly all patients (99 percent) had received one prior VEGF-targeted therapy, 1 percent had received two prior VEGF-targeted therapies, and 18 percent had received prior immunotherapy treatment. The results of this study were presented in an oral presentation at the 2015 annual meeting of the American Society of Clinical Oncology.

Lenvima, sponsored by Eisai, inhibits the kinase activities of vascular endothelial growth factor receptors VEGFR1-3. Lenvima also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor receptors FGFR1-4; the platelet derived growth factor receptor alpha, KIT, and RET.

Lenvima was approved under the Priority Review designation for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer by the FDA in February 2015.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login